Literature DB >> 28926105

Loss of RUNX1 is associated with aggressive lung adenocarcinomas.

Jon Ramsey1, Kelly Butnor2, Zhihua Peng2, Tim Leclair3, Jos van der Velden2, Gary Stein1, Jane Lian1, C Matthew Kinsey4.   

Abstract

The mammalian runt-related factor 1 (RUNX1) is a master transcription factor that regulates lineage specification of hematopoietic stem cells. RUNX1 translocations result in the development of myeloid leukemias. Recently, RUNX1 has been implicated as a tumor suppressor in other cancers. We postulated RUNX1 expression may be associated with lung adenocarcinoma etiology and/or progression. We evaluated the association of RUNX1 mRNA expression with overall survival data from The Cancer Genome Atlas (TCGA), a publically available database. Compared to high expression levels, Low RUNX1 levels from lung adenocarcinomas were associated with a worse overall survival (Hazard Ratio = 2.014 (1.042-3.730 95% confidence interval), log-rank p = 0.035) compared to those that expressed high RUNX1 levels. Further immunohistochemical examination of 85 surgical specimens resected at the University of Vermont Medical Center identified that low RUNX1 protein expression was associated with larger tumors (p = 0.038). Gene expression network analysis was performed on the same subset of TCGA cases that demonstrated differential survival by RUNX1 expression. This analysis, which reveals regulatory relationships, showed that reduced RUNX1 levels were closely linked to upregulation of the transcription factor E2F1. To interrogate this relationship, RUNX1 was depleted in a lung cancer cell line that expresses high levels of RUNX1. Loss of RUNX1 resulted in enhanced proliferation, migration, and invasion. RUNX1 depletion also resulted in increased mRNA expression of E2F1 and multiple E2F1 target genes. Our data implicate loss of RUNX1 as driver of lung adenocarcinoma aggression, potentially through deregulation of the E2F1 pathway.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  RUNX; adenocarcinoma; non-small cell lung cancer; runt related transcription factor

Mesh:

Substances:

Year:  2017        PMID: 28926105      PMCID: PMC5989135          DOI: 10.1002/jcp.26201

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  43 in total

Review 1.  A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.

Authors:  Robert L Camp; Veronique Neumeister; David L Rimm
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

2.  Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway.

Authors:  Ya-Ling Hsu; Ming-Shyan Huang; Chih-Jen Yang; Jen-Yu Hung; Ling-Yu Wu; Po-Lin Kuo
Journal:  J Biol Chem       Date:  2011-09-01       Impact factor: 5.157

3.  Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma.

Authors:  Y Tomizawa; J Adachi; T Kohno; K Hamada; R Saito; M Noguchi; Y Matsuno; S Hirohashi; N Yamaguchi; J Yokota
Journal:  Clin Cancer Res       Date:  1999-05       Impact factor: 12.531

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion.

Authors:  Jitesh Pratap; Amjad Javed; Lucia R Languino; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

6.  Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.

Authors:  You-Soub Lee; Jung-Won Lee; Ju-Won Jang; Xin-Zi Chi; Jang-Hyun Kim; Ying-Hui Li; Min-Kyu Kim; Da-Mi Kim; Byeung-Sub Choi; Eung-Gook Kim; Jin-Haeng Chung; Ok-Jun Lee; You-Mie Lee; Joo-Won Suh; Linda Shyue Huey Chuang; Yoshiaki Ito; Suk-Chul Bae
Journal:  Cancer Cell       Date:  2013-11-11       Impact factor: 31.743

7.  E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.

Authors:  Cheng-long Huang; Dage Liu; Jun Nakano; Hiroyasu Yokomise; Masaki Ueno; Kyuichi Kadota; Hiromi Wada
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

8.  Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells.

Authors:  Manish Tandon; Karthiga Gokul; Syed A Ali; Zujian Chen; Jane Lian; Gary S Stein; Jitesh Pratap
Journal:  Mol Cancer       Date:  2012-06-18       Impact factor: 27.401

9.  Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition.

Authors:  Deli Hong; Terri L Messier; Coralee E Tye; Jason R Dobson; Andrew J Fritz; Kenneth R Sikora; Gillian Browne; Janet L Stein; Jane B Lian; Gary S Stein
Journal:  Oncotarget       Date:  2017-03-14

10.  Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Authors:  J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more
  9 in total

Review 1.  RUNX1-dependent mechanisms in biological control and dysregulation in cancer.

Authors:  Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

2.  Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma.

Authors:  Lindsay M LaFave; Vinay K Kartha; Sai Ma; Kevin Meli; Isabella Del Priore; Caleb Lareau; Santiago Naranjo; Peter M K Westcott; Fabiana M Duarte; Venkat Sankar; Zachary Chiang; Alison Brack; Travis Law; Haley Hauck; Annalisa Okimoto; Aviv Regev; Jason D Buenrostro; Tyler Jacks
Journal:  Cancer Cell       Date:  2020-07-23       Impact factor: 31.743

3.  RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.

Authors:  Haiwei Wang; Xinrui Wang; Ji Zhang; Liangpu Xu; Hua Cao
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

4.  miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1.

Authors:  Shichao Han; Jinming Zhu; Yilei Zhang
Journal:  Med Sci Monit Basic Res       Date:  2018-02-15

5.  Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis.

Authors:  Yang Fu; Shanshan Sun; Xiaojun Man; Chuize Kong
Journal:  PeerJ       Date:  2019-10-02       Impact factor: 2.984

6.  LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells.

Authors:  Liankang Sun; Liang Wang; Tianxiang Chen; Yu Shi; Bowen Yao; Zhikui Liu; Yufeng Wang; Qing Li; Runkun Liu; Yongshen Niu; Kangsheng Tu; Qingguang Liu
Journal:  Cell Death Dis       Date:  2020-02-05       Impact factor: 8.469

7.  Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.

Authors:  Beatriz Andrea Otálora-Otálora; Daniel Alejandro Osuna-Garzón; Michael Steven Carvajal-Parra; Alejandra Cañas; Martín Montecino; Liliana López-Kleine; Adriana Rojas
Journal:  Biology (Basel)       Date:  2022-07-20

8.  CTpathway: a CrossTalk-based pathway enrichment analysis method for cancer research.

Authors:  Haizhou Liu; Mengqin Yuan; Ramkrishna Mitra; Xu Zhou; Min Long; Wanyue Lei; Shunheng Zhou; Yu-E Huang; Fei Hou; Christine M Eischen; Wei Jiang
Journal:  Genome Med       Date:  2022-10-13       Impact factor: 15.266

Review 9.  The Role of RUNX1 in NF1-Related Tumors and Blood Disorders.

Authors:  Youjin Na; Gang Huang; Jianqiang Wu
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 5.034

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.